% | $
Quotes you view appear here for quick access.

Seattle Genetics, Inc. Message Board

  • mghmd mghmd Mar 28, 2013 9:06 AM Flag

    SGEN removed from Top Picks list at Credit Suisse

    and replaced by Endocyte. They comment that the laters delivery system for the cancer cell warhead is superior to SGENs.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Hopefully he is correct because to be better it would need to have pretty close to 100% kill rate thus eradicating cancer. Unfortunately I've seen lots of people blowing smoke just before the flames fizzle.
      For the time being, SGEN technology is out of the lab and saving more lives every day while Endocyte is still in the lab. As promising as the lab results may be they can't be measured up against technology that's in the market yet.
      In time hopefully but not now and until then a bird in the hand is better than 4 in the bush!

    • It appears difficult to determine at this time which of the two methodologies is, or will emerge, generally "superior". Endocyte uses a ligand based system for the delivery of toxic payloads at targeted sites, while Seattle Genetics employs an antibody. Let's also not forget that each specific product, regardless of the underlying technology on which it is built, must be judged on its own merit. Factors such as affinity and specificity for the target, toxicities on non-targeted tissues, plasma stability of the linker and proper release and incorporation of the toxic payload into the target cells, etc. all are unique for each specific drug and to its ultimate clinical usefulness.

      Good luck to all !


55.83-0.36(-0.64%)Sep 23 4:00 PMEDT